GLP-1 receptor agonists — the drug class that includes Ozempic, Wegovy and Mounjaro — were linked to improved survival among colon cancer patients in a new observational study from UC San Diego.
In a viewpoint published Nov. 10 in Medscape, David Johnson, MD, chief of gastroenterology at Eastern Virginia Medical School and Old Dominion University in Norfolk, outlined four studies presented at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback